3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Neoplasm Metastasis
10
Carcinoma, Medullary
10
Thyroid Neoplasms
5
Lung Neoplasms
5
Prostatic Neoplasms
3
Neoplasms
3
Adenocarcinoma
3
Familial medullary thyroid carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Breast Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Differentiated Thyroid Cancer
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Biliary Tract Neoplasms
1
Aggression
1
Advanced Breast Cancer
1
Interventions
Carboplatin
30
Cisplatin
23
pembrolizumab
22
Paclitaxel
21
Pemetrexed
20
Gemcitabine
10
osimertinib
9
durvalumab
9
Nivolumab
9
130-nm albumin-bound paclitaxel
8
Sunitinib
7
Sorafenib
7
Fluorouracil
7
Everolimus
7
Docetaxel
7
Axitinib
7
Cetuximab
6
epothilone B
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
volociximab
4
trebananib
4
reolysin
4
catumaxomab
4
cabozantinib
4
atezolizumab
4
Radiotherapy
4
Ipilimumab
4
vosaroxin
3
liposomal doxorubicin
3
lenvatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma
×
vandetanib
×
Clear all
NCT00506051
2016-08-25
ZD6474(Vandetanib) + Alimta Combo Study
Sanofi
Phase 1
Completed
21 enrolled